Thank recent results update you activities. with update call. financial and pipeline on business on begin for our second will then XXXX TRACON's an joining quarter I review our
XX our financial six Scott Brown, Chief June results months the that will our Financial Following review and for three ended XXXX. Officer
will continued ENVASARC we on I'll taking start with questions. Finally, conclude your progress by an update pivotal our the with trial.
to now robust at patients than milligram IDMC that in XX and our estimates by dose is have at U.K. full more from one ENVASARC, weeks enrollment the dose of the more in milligram the for and three the ahead recommended of U.S. of the open announced reviewed be at We we XXX than This project dose. the XXX patient’s continuous ENVA trial sites XXXX. site XX that enrolled and completed plan patients been data morning, which safety XXX end accrual has XX in of is Accrual
additional two this IDMC expect reviews We year.
XX occurs patients is assessment expected XXth And the that enrollment XX the that following assessment of after expected interim occurs in safety in second fourth enrollment of the efficacy weeks is The patient October. three quarter. months the
Note which a of dose. a two an Committee dose. was that XX XXX apply prompted received dose XX in the the the efficacy recommend futility rate that the XXX patients, milligrams. to in each the milligram ENVA who to time, and During response response Recall the interim at assessment, increasing analysis higher observed weight the threshold XXX was performed IDMC lighter last year at significantly the futility milligram cohorts least the will in achieved requires rule interim patients identical in at ENVA at one patients
endpoint. X% plan we filing sarcoma in in As and refractory agent demonstration response of is review Furthermore, of in the and We Votrient. approved other refractory reminder, refractory cohort a approach Based soon toxicity. on satisfies for ENVA you drug objective second of are a by discuss response the of Notably box to only MFS, XX% XX% ENVA or as blinded of duration In the FDA either believe key as warning with transform the review the patients and strategy to the being that rate each objective fatal from compared receive single demonstration UPS response of primary objective potential received cohort. a one response, rate the a agent responses of data checkpoint cohort, with of single rate with through the a Votrient nine to superior for efficacy rate with to objective is care given targeting response up as ENVA endpoint we secondary resist, each for BLA rate includes inhibitors responses out XX.XX% ENVA we UPS level by liver combination trials The patients determine a cohort the central and and independent XX who to ENVA is Votrient, response by confirmed black with a has safety a X Yervoy. MFS. exceed Yervoy. ENVASARC to study, response an the trial of cohort for central statistically which defines objective treatment primary in
FDA track this and agency with response year. ENVASARC, the have we fast designation in on later from Finally, based activity a already expect observed applied the
Earlier patients from YHXXX including who submitted a ENVA sarcoma prior this licensed trial Our initiation doxorubicin the have best-in-class of last year. an X/X therapy. the CTLA-X combination Phase and application potential IND Eucure in of a month, of checkpoint the inhibitor not we we patients, treatment in received antibody with clinical YHXXXis FDA October second to Biopharma for for
reminder, license American to and in cancer, we microsatellite develop including broad other North a cancer. a and As YHXXX lung stable received and carcinoma, multiple sarcoma, commercialize colorectal cell renal indications, in KRAS-positive
substitute could with at included Now, marketed license, standard to respect those PDX our of existing or non-sarcoma endometrial care melanoma election. our indications YHXXX for of In with can cancer be we combined any cancer, bladder these agents antibodies. one indications,
These recommended trials Eucure. a initial Our in conducted X X agent, two PD-X the YHXXX single of two Phase a demonstrated the toripalimab. dose and as from combination by Phase trial partner antibody, trials with data leverages YHXXX
trial clinical includes is evaluate YHXXX, for X/X doxorubicin doxorubicin chemotherapy, ENVA frontline that standard-of-care triplet and Phase sponsored treatment Our will current the a sarcoma. as
therapy portion trial combination as Following the that doublet, doxorubicin. tolerability ENVA of of YHXXX the assess Phase the X triple as well of the includes to and the the
and not single subtypes and standard-of-care is In alveolar of where of the rate study response with or demonstrating to common combination agent sarcoma, sarcoma leiomyosarcoma, effective, single inhibition. the assess rare therapy doxorubicin. to to liposarcoma, the chemotherapy, chemotherapy historical the compared YHXXX plan rates agents. we the response of intend agent rates historical using of will of in treatment assess data and rate soft response response In XX% checkpoint triple and to to intent the to We response rate case compared highly with XX% leiomyosarcoma, the superior historical we response rate doublet to sarcoma subtypes compare ENVA the rare part to
is this of ENVA that YHXXX One respond of sarcoma subtypes combination trial the and X/X the doxorubicin. of purposes to best the to of Phase determine
pivotal trial ENVA, survival ENVASARC approval positive trial results FDA a of trial, a the Following in potential assuming the benefit. demonstrate accelerated randomized the require to
licensed immune sarcoma the benefit. the demonstrated. ENVA activity pricing therapies in great potential sarcoma therapy, revenues the to post as of solely the from of the understand PFS expected sarcoma rare data million UPS sales ENVA to to refractor as Phase expected rural with MFS sarcoma as triple that trial in is on ability inhibition to be for strategic X/X million We The doxorubicin MFS and commercialize with combination to is well described oncology and now in earlier. other This and single triplet revenue $XXX initial subtypes trial has a indications UPS in of endpoint. respond trial at forecasts I approval patients is based compare at to important will $XXX with to in subtypes together ENVA TRACON shown Phase annual YHXXX in expect and the X would its the doxorubicin well agent where as with been the checkpoint It annual
adjuvant and clinical neoadjuvant be opportunity Moreover, Our sarcoma YHXXX settings indications. to broadly revenue by believe seeking supplemental in enhanced for a designed total benefit by treatment to strategy is would significantly development marketing with as the TRACONS sarcoma sales of create part frontline, patients ENVA in we the driven sarcoma. together and ENVA combination
of patients two XX% trial's our in detect The consolidative therapy X primary has two pleased at enroll randomized to of Cancer repair initiated we fund the non-small and radiation lung National TRCXXX current XXXX. to addition durvalumab of XX%. Results fall the cancer will the combination PFS to inhibitors, TRCXXX expected treatment. Cancer benefit of trials to improvement The are one-year in three, cisplatin assess the endpoint standard-of-care XX development Institute designed PFS are Phase non-squamous, a that in The by trial stage arm our National assessing Institute an continues from trial checkpoint and chemo adding In pemetrexed, damage radiation. inhibitor treatment with in cell TRCXXX. DNA to to
clinical combination inhibitor a antibody last complete We're X the with which fourth the has agent checkpoint patient. TJXXXX asset tri-centric. enrolled Our working evaluating study is to in is Phase a analysis the TRACON as a and single stage data CDXX of that trial in
the desire their completion TRACON I-Mab to a license following reminder, a X Phase TJXXXX terminate trial As million. has $X option payment for to their the to of exercise of indicated
expected the be we quarter, for are of million. the will I-Mabs now testing completed this be the clinical results option sample that TJ study end the then would completed triggers While require This XXX of expect final to by second quarter. we awaiting $X we
on will provide our update I-Mab. disputes with Next, legal an I
briefs meet terms post to the York the of heard this for both if XXXX. in complex. As that TRACON results ICC awarded Chamber us may party submitted into under further $XXX concerning prevailing are although provisions, were year, to be arbitration the in rules XXXX. In of discretion. arbitration, November final late tribunal the its a filed the are I-Mab be of before alleged awarded million the Court arbitration that contractual outcome at I-Mab attorney’s if under and to damages the commenced law, to over Pending the of tribunal the the amount unable of February of seeking arbitration agreements invoke the Accordingly, by the cannot After continue the based I-Mab our On asserting International also Under a may agreements we a of the September had Commerce obligations breaches. contractual X, both June arbitration, breaches estimate XX, the We Tribunal dispute any of from the predict and of Arbitration recovery under obligations in with the in arguments I-Mab expect the resolution breached May. decision of alleged tribunals tribunal. reminder, warranted. of June notified New we may on counterclaims both of entered arbitration International by for final ask of hearing damages ICC in recover to arbitration, were The extension agreements. claims the we an applicable our fees our
the when We will tribunal an their provide announced promptly panel update findings.
capital runway source. issuance corporate common pre June Given in markets, common transaction of capital important. we market extends warrants meantime, shareholder, largest OCLI another of the to non-dilutive first half the Capital our and our from secure capital XXXX. without the funded this In recently is partners through cash $X at from expectation warrants. purchase secured our million the stock into price challenge the in In
X million runway arbitration further intent extended by the $X extended this their the to be stated be will to any Phase expected year TJXXXX payment later related and trial Our I-Mab to would completion award. following from of require further
opportunities CRO we for As through capital efficient that of we our most through non-dilutive development product enabled cancellation supplement our to the us the organizations. independent development as in positions we past, believe have clinical platform one noted further expect
our for platform to leverage expect to capital TRACON. ways to that provide We in continue two non-dilutive potential
performs First, we model structure TRACON use that the we're trials costs by candidates a royalties the but were cost than Johnson. example, and using to by still for premium a benefits at at share evaluating & performance revenue, CRO, our from earning past, clinical a fees a TRACON pay for drug commercialization. lower in licensing Johnson aligned further sub is This with of including an a
proprietary paid clinical Second, trials. we're exploring new with our how model company execute another a internalize CROs clinical contract we're enable to franchise these operations know avoid to use to capabilities and to and to whereby thing independently capabilities share
experience be development substantial platform for to wish quality, of result credibility an Scott As time, our typically has earned has CRO an rewards We at update costs strong been contracted on become financials. a trials our this the conducting trials compared for and overtime, savings partner. of reap such expected provide lower time to At independent, solution faster, and to companies as product would believe in that cost compelling and TRACON investment our the will who to CROs. higher
